Overview and Clinical Presentation

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves, causing progressive muscle weakness, sensory dysfunction, and impaired nerve conduction due to inflammation and demyelination. It involves immune-mediated attacks by T-cells, macrophages, and autoantibodies disrupting the myelin sheath. CIDP can affect all ages, more commonly middle-aged and older adults, and is associated with conditions like systemic lupus erythematosus, HIV, and hepatitis. Symptoms typically include symmetrical limb weakness, numbness, tingling, and balance difficulties, with variable clinical phenotypes including sensory-predominant and atypical forms. Autoantibodies against nerve proteins may influence presentation and treatment response.

Diagnosis

Diagnosis relies on medical history, neurological examination, and electrophysiological studies such as nerve conduction studies and electromyography to detect demyelination. Supportive tests include cerebrospinal fluid analysis showing elevated protein without increased cells, nerve ultrasound, MRI neurography, and, in select cases, nerve biopsy to exclude other neuropathies. Some patients may not meet strict diagnostic criteria but still respond to immunomodulatory therapies, highlighting diagnostic complexity.

Treatment

Early treatment aims to modulate the immune system and prevent nerve damage. First-line therapies include corticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange. Corticosteroids improve symptoms in about 60% of patients but carry risk of side effects. IVIg, including subcutaneous forms, modulates immunity and has demonstrated dose-dependent efficacy; novel agents like Efgartigimod, targeting the neonatal Fc receptor, show promising results in reducing relapses. Plasma exchange removes pathogenic antibodies and is reserved for refractory cases. Second-line immunosuppressants may be used when first-line treatments fail, though evidence is limited. Symptomatic management addresses neuropathic pain and fatigue with medications and supportive measures.

Rehabilitation and Supportive Care

Multidisciplinary rehabilitation is essential to improve function and quality of life, involving physical therapy to enhance strength, balance, and flexibility through tailored exercise programs using energy conservation techniques. Occupational therapy supports fine motor skills, while psychological support addresses depression and anxiety. Outcome measures guide progress and treatment adjustments. Interprofessional collaboration ensures comprehensive care from diagnosis through long-term management.

Prognosis

Prognosis varies by age at onset, disease subtype, and treatment response. Younger patients and those with relapsing or monophasic forms tend to fare better. Approximately two-thirds experience progressive disease, while others have relapsing episodes. Early treatment generally improves outcomes. Ongoing management and rehabilitation are often necessary due to the chronic, fluctuating nature of CIDP.

Research and Future Directions

Research focuses on expanding therapeutic options beyond standard immunomodulation to improve outcomes, with recent advances including subcutaneous immunotherapies like Efgartigimod that reduce relapse risk and enhance convenience. Additional monoclonal antibodies, such as nipocalimab, are under investigation. Challenges remain in balancing immunosuppression benefits with infection risks. Advances in electrophysiologic diagnostics support earlier, accurate detection. Multidisciplinary care remains vital to optimize individualized treatment strategies.

Patient Resources and Support

Comprehensive care for CIDP addresses physical, emotional, and psychological needs through a coordinated team of healthcare professionals. Psychologists help manage mental health challenges, while physiotherapists and occupational therapists provide interventions to maintain mobility and function. Patient education and engagement promote self-management and safety. Advocacy organizations offer additional support and resources to empower patients.

The content is provided by Sierra Knightley, The True Signal